secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001628280-22-032097
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports positive Phase 3 results for roflumilast cream 0.15% in atopic dermatitis
--------------------------------------------------------------------------------

- INTEGUMENT-1: 32.0% of roflumilast patients achieved IGA success vs 15.2% vehicle (p<0.0001); INTEGUMENT-2: 28.9% vs 12.0% (p<0.0001).
- Key secondary endpoints met: EASI-75 (43.2% vs 22% in INTEGUMENT-1) and WI-NRS itch reduction (33.6% vs 20.7% in INTEGUMENT-1) at week 4.
- Roflumilast cream was well-tolerated with low TEAEs; discontinuation rates low (<2%) in both trials.
- Total 1,337 subjects enrolled across both trials (654 in INTEGUMENT-1, 683 in INTEGUMENT-2); completed study rates ~93% and 90%.
- Company posted updated corporate presentation with trial details; results support potential NDA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022032097/0001628280-22-032097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022032097/arqt-20221212.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-032097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer